A Phase IV, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBe-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2a 40kD (Peg-IFN) ± Nucleos(t)Ide Analogue

Trial Profile

A Phase IV, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBe-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2a 40kD (Peg-IFN) ± Nucleos(t)Ide Analogue

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Adefovir; Entecavir; Lamivudine
  • Indications Hepatitis B
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 07 Apr 2016 Trial focus changed from TU to PD as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials. gov.
    • 12 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials. gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top